Aim: The aim of this study is to analyse avaliable medical data of patients diagnosed with multiple myeloma (MM), lymphoma Hodgkin (MB) and non-Hodgkin (NHL) and acute leukemia (AL), who underwent ASCT, and to compare the results with the results from other scientific works.
Introduction: Autologous stem cell transplantation (ASCT) with high dose chemotherapy is effectible and safe approach in the treatment of different hematological malignancies. Nowdays, it is the standard therapy for multiple myeloma, lymphomas and acute leukemias.
Methods: Retrospective study included 84 patient diagnosed with MM, MH, LNH and AL who underwent ASCT in the period from 2004 to 2016. Data are presented in table and charts.
Results: In relation to the underlying disease, the distribution of respondents was as follows: 35 patients with MM, 24 with NHL, 20 with MH and 6 with AL. Large volume apheresis procedure had to 75 patients (89.3%), and 9 patients (10.7%) had conventional two-day procedure. The mean value of processed blood volume amounted to 13050ml. The average number of MNC in the apheresis product was 7.8×108/kg bw, a CD34+ cells was 12.11×106kg bw. After the application of conditioning regimens, depending on the underlying disease, neutrophils engraftment occurs at 11 day and platelets engraftment at 14 day.
Conclusion: Analyzing data of the patients with hematological malignancies and ASCT conducted, we conclude that the mentioned procedure is successful method of treatment, with low transplant mortality and complications caused by the mentioned procedure.